Home / University / Fundraising / Support of research projects / Research topic Molecular Oncology and Hematology

Research topic Molecular Oncology and Hematology

The research topic Molecular Oncology and Hematology focuses on the development of innovative therapeutic anticancer agents.

Health policy relevance of tumor diseases

Currently, about 350,000 people are living with a diagnosis of cancer in Austria; of these, 40,000 are newly diagnosed each year. Around 20,000 people, i.e.  a quarter of all deaths per year, die from their tumor disease. Due to the general increase in life expectancy, but also improved screening and diagnostic methods, these numbers will increase considerably in the coming years. In fact, the incidence of cancer has increased by 35% between 2006 and 2016. At the same time, however, cancer survival rates have improved, further increasing the number of people living with cancer. Thus, tumor diseases are of highest health policy relevance.

Objectives of the Molecular Oncology and Hematology Research Group

The Scientific Working Group has two principle goals:  primarily to advance the understanding of the epidemiology and prognosis of specific tumor diseases, plus the research of molecular basics of oncological/hematological tumor diseases and the development of new diagnostics, therapeutics and innovative therapy strategies derived from them.

Research focus

The research of the Molecular Oncology and Hematology Group would not be possible without the continuous support of funding institutions, grants, research support from industry and dedicated donors. Current research projects that can be supported include the following:

Ongoing research projects in the group include pathophysiological elucidation of multiple myeloma and breast carcinoma. Multiple myeloma (cancer of the bone marrow) is the second most common malignant hematological tumor disease. Mammary carcinoma (breast cancer) is the most common tumor disease in women.

Another focus is the identification of molecular mechanisms leading to tumor-associated bone disease. The goal of this research focus is to develop new diagnostics, prognostics and therapeutics.

Your support

Even small contributions help to purchase necessary consumables (chemicals, antibodies, assay kits, plasticware), and thus advance the progress of oncological/hematological research for the benefit of our tumor patients.

You are interested in supporting a research topic? 

Please contact us for further information. 

Podar Klaus

Priv.-Doz. Mag. DDr. Klaus Podar

Head of Working Group "Molecular Oncology/Hematology"

Events

  1. 15 Dec

    KL Lunchtime Seminar: Towards Natural Killer Cell-Based Immune Therapy in Leukemia

    15. December 2021, 12:00 - 13:00
    Karl Landsteiner University, 3500 Krems/Donau, Wing Y, KL Auditorium
  2. 19 Jan

    KL Lunchtime Seminar: Extramedullary hematopoiesis as part of the innate immune defence against infections

    19. January 2022, 12:00 - 13:00
    Karl Landsteiner University, 3500 Krems/Donau, Wing Y, KL Auditorium
  3. 26 Jan

    KL Lunchtime Seminar: Mechanisms of solute transport through cellular membranes

    26. January 2022, 12:00 - 13:00
    Karl Landsteiner University, 3500 Krems/Donau, Wing Y, KL Auditorium